Fundraising Fox
/Companies
Sign in

4D Molecular Therapeutics

NASDAQ: FDMT

Emeryville, US · Founded 2015 · Delaware corporation · 23 known investors

Find your way into 4D Molecular Therapeutics

1,251 people in our graph share verified history with the 4D Molecular Therapeutics team — schools, employers, funds. One of them is your warm intro.

Shahram Seyedin-Noorunlockedknows David Schaffer · together at Rewrite Therapeutics (overlapped)
knows the team · via Salk Institute for Biological Studies
×10knows the team · via Johnson & Johnson

4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases. The company uses its Therapeutic Vector Evolution platform to design customized vectors for targeted treatment delivery.

BiotechHealthtech

Founders & leadership

4D Molecular Therapeutics was founded in 2015 by David Kirn and David Schaffer.

DKDavid Kirn
David KirnCo-Founder & CEODavid Kirn is a physician and biotech entrepreneur with expertise in viral vector-based therapeutics and gene therapy. He previously founded and led multiple gene therapy platform companies through clinical development stages and holds a faculty position at UC Berkeley.
DSDavid Schaffer
David SchafferCo-Founder, Chief Scientific Advisor, Director2012–2022Director of 4D Molecular Therapeutics, where he leads research in bioengineering and gene therapy, with expertise in signal transduction, gene regulation networks, and viral vector development for therapeutic applications.
TJ
Theresa JankeChief Of StaffTheresa Janke is an executive in biotechnology with experience in viral vector development, gene therapy, clinical operations, and business development. She holds a Bachelor of Science in Biopsychology from UC Santa Barbara.

Board

ST
Sharon TetlowBoard director
MM
Margi McLoughlinBoard director

Investors · 23

Berkeley Catalystlisted by Berkeley CatalystBerkeley

How we know: the VCSheet dataset · Not right? Tell us

BOLD Longevitylisted by BOLD LongevityBoston
Chiesi Ventureslisted by Chiesi VenturesBoston · $5M

How we know: Chiesi Ventures's portfolio page · press coverage · Not right? Tell us

Pappas Capitallisted by Pappas CapitalDurham
Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us

Ridgeback Capitallisted by Ridgeback CapitalNew York

How we know: Ridgeback Capital's portfolio page · Not right? Tell us

Biotechnology Value FundreportedSan Francisco

How we know: pappas-capital.com · Not right? Tell us

Casdin CapitalreportedNew York

How we know: funding news · pappas-capital.com · Not right? Tell us

Janus Henderson InvestorsreportedLondon

How we know: press coverage · Not right? Tell us

Pappas CapitalreportedResearch Triangle Park · $100K – $6M

How we know: press coverage · Not right? Tell us

Pfizer Venturesreported

How we know: pappas-capital.com · Not right? Tell us

Viking Global InvestorsreportedStamford

How we know: funding news · pappas-capital.com · Not right? Tell us

Also in the syndicate · 10

Arrowmark PartnersBerkeley Catalyst FundCystic Fibrosis FoundationLongevity Vision FundMiraeAsset Financial GroupOctagon InvestmentsPappas Capital & Chiesi VenturesPerceptive AdvisorsQUAD Investment ManagementRidgeback Capital Investments

Funding

SEC filings, press & company announcements

$108.6M disclosed across 3 of 4 rounds · 2015–2020

▶$90MraisedSep 2018 · 31 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Theresa JankeExecutive Officer
  • Margi McLaughlinDirector
  • David Kirn, M.D.Executive Officer, Director
  • Peter Francis, M.D.Executive Officer
  • Hoyoung Huh, M.D., Ph.D.Director
  • Leisa Johnson, Ph.D.Executive Officer
  • Charles Theuer, Ph.D.Director
  • David Schaffer, Ph.D.,Executive Officer, Director
  • Tony YaoDirector
Offering amount
$90M
Amount sold
$90M
First sale
Aug 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.6MraisedOct 2015 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David KirnExecutive Officer, Director
  • Theresa JankeExecutive Officer
  • Sharon TetlowDirector
  • Margi McLoughlinDirector
  • David SchafferDirector
Offering amount
$11.6M
Amount sold
$11.6M
First sale
Oct 2015
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7MraisedAug 2015 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David SchafferDirector
  • David KirnExecutive Officer, Director
  • Theresa JankeExecutive Officer
Offering amount
$7M
Amount sold
$7M
First sale
Aug 2015
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does 4D Molecular Therapeutics do?
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases. The company uses its Therapeutic Vector Evolution platform to design customized vectors for targeted treatment delivery.
Who founded 4D Molecular Therapeutics?
4D Molecular Therapeutics was founded by David Kirn, David Schaffer in 2015.
Who are 4D Molecular Therapeutics's investors?
4D Molecular Therapeutics's investors include Amzak Health, Berkeley Catalyst, BOLD Longevity, Chiesi Ventures, Pappas Capital, Pfizer Venture Investments, Ridgeback Capital, Biotechnology Value Fund and 5 more.
How much funding has 4D Molecular Therapeutics raised?
4D Molecular Therapeutics has disclosed $108.6M raised across 3 of its 4 known rounds.
Where is 4D Molecular Therapeutics headquartered?
4D Molecular Therapeutics is headquartered in Emeryville, US.